Joby Aviation (JOBY) 10-Q 5 May 23 2023 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2023	May 03, 2023
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-39524
Entity Registrant Name	Joby Aviation, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	98-1548118
Entity Address, Address Line One	333 Encinal Street
Entity Address, City or Town	Santa Cruz
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95060
City Area Code	831
Local Phone Number	201-6700
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		630,978,702
Entity Central Index Key	0001819848
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Amendment Flag	false
Common Stock
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.0001
Trading Symbol	JOBY
Security Exchange Name	NYSE
Common stock warrants
Document Information [Line Items]
Title of 12(b) Security	Warrants to purchase common stock
Trading Symbol	JOBY WS
Security Exchange Name	NYSE

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 49,795	$ 146,101
Short-term investments	927,980	910,692
Total cash, cash equivalents and short-term investments	977,775	1,056,793
Restricted cash	2,235	3,204
Other receivables	10,912	4,021
Prepaid expenses and other current assets	22,218	20,160
Total current assets	1,013,140	1,084,178
Property and equipment, net	93,032	92,103
Operating lease right-of-use assets	24,023	25,149
Restricted cash	762	762
Intangible assets	11,085	12,581
Goodwill	14,011	14,011
Other non-current assets	62,674	64,200
Total assets	1,218,727	1,292,984
Current liabilities:
Accounts payable	3,927	7,710
Operating lease liabilities, current portion	3,546	3,710
Accrued and other current liabilities	22,844	18,783
Total current liabilities	30,317	30,203
Operating lease liabilities, net of current portion	22,684	23,613
Warrant liability	37,814	28,783
Earnout shares liability	57,094	44,055
Other non-current liabilities	1,323	1,589
Total liabilities	149,232	128,243
Commitments and contingencies (Note 6)
Stockholders’ equity:
Preferred stock: $0.0001 par value - 100,000,000 shares authorized. No shares issued and outstanding.	0	0
Common stock: $0.0001 par value - 1,400,000,000 shares authorized; 629,522,605 and 622,602,815 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively.	61	61
Additional paid-in capital	1,923,054	1,908,179
Accumulated deficit	(848,046)	(734,653)
Accumulated other comprehensive loss	(5,574)	(8,846)
Total stockholders’ equity	1,069,495	1,164,741
Total liabilities and stockholders’ equity	$ 1,218,727	$ 1,292,984

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Preferred stock , par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock shares authorized (in shares)	100,000,000	100,000,000
Preferred stock, shares Issued (in shares)	0	0
Preferred stock shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	1,400,000,000	1,400,000,000
Common stock, shares, issued (in shares)	629,522,605	622,602,815
Common stock, shares outstanding (in shares)	629,522,605	622,602,815

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating expenses:
Research and development (including related party purchases of $128 and $644 for the three months ended March 31, 2023 and 2022, respectively.)	$ 75,518	$ 72,071
Selling, general and administrative (including related party purchases of $24 and $161 for the three months ended March 31, 2023 and 2022, respectively.)	24,198	22,272
Total operating expenses	99,716	94,343
Loss from operations	(99,716)	(94,343)
Interest and other income, net	8,400	757
Income from equity method investment	0	14,458
Gain (Loss) from change in fair value of warrants and earnout shares	(22,043)	16,814
Total other income (loss), net	(13,643)	32,029
Loss before income taxes	(113,359)	(62,314)
Income tax expense	34	5
Net loss	$ (113,393)	$ (62,319)
Net loss per share, basic (in dollars per share)	$ (0.19)	$ (0.11)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.19)	$ (0.11)
Weighted average number of shares outstanding, basic (in shares)	605,184,671	579,090,606
Weighted average number of shares outstanding, diluted (in shares)	605,184,671	579,090,606

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Parenthetical) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Research and development, related party purchases	$ 128	$ 644
Selling, general and administrative, related party purchases	$ 24	$ 161

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement of Comprehensive Income [Abstract]
Net loss	$ (113,393)	$ (62,319)
Other comprehensive gain (loss):
Unrealized gain (loss) on available-for-sale securities	3,245	(2,596)
Foreign currency translation gain	27	38
Total other comprehensive gain (loss)	3,272	(2,558)
Comprehensive loss	$ (110,121)	$ (64,877)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Beginning balance at Dec. 31, 2021	$ 1,316,759	$ 60	$ 1,793,431	$ (476,610)	$ (122)
Common stock, beginning balance (in shares) at Dec. 31, 2021		604,174,329
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(62,319)			(62,319)
Stock-based compensation	12,088		12,088
Issuance of common stock upon exercise of stock options (in shares)		823,524
Issuance of common stock upon exercise of stock options	428		428
Issuance of common stock upon release of restricted stock units (in shares)		851,557
Vesting of early exercised stock options and common stock issued in private placement	121		121
Stock withheld related to net share settlement (in shares)		(13,041)
Shares withheld related to net share settlement	(85)		(85)
Other comprehensive loss	(2,558)				(2,558)
Common stock, ending balance (in shares) at Mar. 31, 2022		605,836,369
Ending balance at Mar. 31, 2022	1,264,434	$ 60	1,805,983	(538,929)	(2,680)
Beginning balance at Dec. 31, 2022	$ 1,164,741	$ 61	1,908,179	(734,653)	(8,846)
Common stock, beginning balance (in shares) at Dec. 31, 2022	622,602,815	622,602,815
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ (113,393)			(113,393)
Stock-based compensation	14,157		14,157
Issuance of common stock upon exercise of stock options (in shares)		945,803
Issuance of common stock upon exercise of stock options	614		614
Issuance of common stock upon release of restricted stock units (in shares)		5,836,813
Vesting of early exercised stock options and common stock issued in private placement	104		104
Issuance of common stock in private placement (in shares)		137,174
Other comprehensive loss	$ 3,272				3,272
Common stock, ending balance (in shares) at Mar. 31, 2023	629,522,605	629,522,605
Ending balance at Mar. 31, 2023	$ 1,069,495	$ 61	$ 1,923,054	$ (848,046)	$ (5,574)

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities
Net loss	$ (113,393)	$ (62,319)
Reconciliation of net loss to net cash used in operating activities:
Depreciation and amortization expense	7,067	5,212
Stock-based compensation expense	17,258	19,429
Loss (Gain) from change in the fair value of warrants and earnout shares	22,070	(16,814)
Income from equity method investment	0	(14,458)
Net accretion and amortization of investments in marketable debt securities	(3,670)	774
Changes in operating assets and liabilities
Other receivables and prepaid expenses and other current assets	(8,517)	418
Other non-current assets	2,629	9,332
Accounts payable and accrued and other liabilities	(1,083)	(3,000)
Non-current liabilities	(929)	0
Net cash used in operating activities	(78,568)	(61,426)
Cash flows from investing activities
Purchase of marketable securities	(126,445)	(571,890)
Proceeds from sales and maturities of marketable securities	116,072	108,056
Purchases of property and equipment	(8,756)	(10,833)
Acquisition, net of cash	0	(1,465)
Net cash used in investing activities	(19,129)	(476,132)
Cash flows from financing activities
Proceeds from issuance of common stock in private placement	50	0
Proceeds from the exercise of stock options	612	342
Repayments of tenant improvement loan and obligations under finance and capital lease	(240)	(262)
Net cash provided by financing activities	422	80
Net change in cash, cash equivalents and restricted cash	(97,275)	(537,478)
Cash, cash equivalents and restricted cash, at the beginning of the period	150,067	956,325
Cash, cash equivalents and restricted cash, at the end of the period	52,792	418,847
Reconciliation of cash, cash equivalents and restricted cash to balance sheets
Cash and cash equivalents	49,795	417,116
Restricted cash	2,997	1,731
Cash, cash equivalents and restricted cash	52,792	418,847
Non-cash investing and financing activities
Unpaid property and equipment purchases	1,357	426
Property and equipment purchased through capital leases	$ 0	$ 252

Company and Nature of Business

Company and Nature of Business	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Company and Nature of Business	Company and Nature of Business Description of Business Joby Aviation, Inc. (“Joby Aviation” or the “Company”) is a vertically integrated air mobility company that is building a clean, quiet, fully-electric vertical takeoff and landing (“eVTOL”) aircraft to be used by the Company to deliver air transportation as a service. The Company is headquartered in Santa Cruz, California. Merger with RTP On August 10, 2021 (the “Closing Date”), Reinvent Technology Partners, a Cayman Islands exempted company and special purpose acquisition company (“RTP”), completed the transactions contemplated by that certain Agreement and Plan of Merger (the “Merger Agreement”), dated as of February 23, 2021, by and among RTP, RTP Merger Sub Inc., a Delaware corporation and wholly-owned subsidiary of RTP (“RTP Merger Sub”), and Joby Aero, Inc., a Delaware corporation (“Legacy Joby”). On the Closing Date, RTP was domesticated as a Delaware corporation, Merger Sub merged with and into Legacy Joby and the separate corporate existence of Merger Sub ceased (the “Merger”), and Legacy Joby survived as a wholly-owned subsidiary of RTP, which changed its name to Joby Aviation, Inc. In connection with the execution of the Merger Agreement, RTP entered into separate subscription agreements (each a “Subscription Agreement”) with a number of investors (each a “PIPE Investor”), pursuant to which the PIPE Investors agreed to purchase, and RTP agreed to sell to the PIPE Investors, shares of Common Stock (“PIPE Shares”), in a private placement (“PIPE Financing”). The PIPE Financing closed substantially concurrently with the consummation of the Merger.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The Condensed Consolidated Financial Statements are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position, results of operations and cash flows for the periods presented. The Condensed Consolidated Financial Statements include accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. There have been no changes to the Company’s significant accounting policies described in Note 2 “Summary of Significant Accounting Policies” to the audited Consolidated Financial Statements in the Company’s annual report on Form 10-K for the year ended December 31, 2022, that have had a material impact on the Condensed Consolidated Financial Statements and related notes. Certain information and footnote disclosures normally included in the Company’s annual audited Consolidated Financial Statements and accompanying notes have been condensed or omitted in these accompanying interim Condensed Consolidated Financial Statements and footnotes. Accordingly, the accompanying interim Condensed Consolidated Financial Statements included herein should be read in conjunction with the audited Consolidated Financial Statements and accompanying notes included in the Company’s annual report on Form 10-K for the year ended December 31, 2022. The results of operations presented in this quarterly report on Form 10-Q are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2023, any other interim periods, or any future year or period. In the opinion of management, these unaudited Condensed Consolidated Financial Statements include all adjustments and accruals, consisting only of normal, recurring adjustments that are necessary for a fair statement of the results of all interim periods reported herein. Cash, Cash Equivalents, and Restricted Cash The Company considers all highly liquid investments with remaining original maturity of three months or less, from the date of purchase, to be cash and cash equivalents. The recorded carrying amount of cash and cash equivalents approximates their fair value. At March 31, 2023 and December 31, 2022, restricted cash primarily related to (i) approximately $2.2 million of cash temporarily retained by the Company to satisfy the Company’s post-closing indemnification claims, if any, against the seller, in connection with the acquisition of an aerospace software engineering company in May 2022 (Note 4) and (ii) a security deposit for a lease obligation of approximately $0.8 million. Additionally, at December 31, 2022, restricted cash included collateral on a letter of credit associated with key equipment purchases of approximately $1.0 million which was settled during the three months ended March 31, 2023. Investment in SummerBio, LLC Following the outbreak of the COVID-19 pandemic, the Company’s management determined that certain previously developed technology that was accessible to the Company could be repurposed and applied in providing high-volume rapid COVID-19 testing through its investment in SummerBio, LLC (“SummerBio”), a related party. The Company has determined that it is not the primary beneficiary of SummerBio. Therefore, it accounts for its investment in SummerBio under the equity method of accounting with an ownership interest of approximately 44.5% as of March 31, 2023 and December 31, 2022. In June 2022, SummerBio notified the Company of its decision to wind down testing operations and close the business, which SummerBio substantially completed by the end of December 2022. The Company recognized income of nil and $14.5 million for the three months ended March 31, 2023 and 2022, respectively, within income from equity method investment on the condensed consolidated statement of operations for its investment in SummerBio. New Accounting Pronouncements Not Yet Adopted There are no recent accounting pronouncements applicable to the Company pending adoption that the Company expects will have a material impact on our condensed consolidated financial condition, results of operations, or cash flows.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Assets and liabilities recorded at fair value on a recurring basis in the condensed consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value represents the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: • Level 1 - Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date; • Level 2 - Inputs are observable, unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and • Level 3 - Unobservable inputs that are significant to the measurement of the fair value of the assets or liabilities that are supported by little or no market data. A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The Company’s financial assets consist of Level 1 and 2 assets. The Company classifies its cash equivalents and marketable debt securities within Level 1 or Level 2 because they are valued using either quoted market prices or inputs other than quoted prices which are directly or indirectly observable in the market, including readily-available pricing sources for the identical underlying security which may not be actively traded. The Company’s fixed income available-for-sale securities consist of high quality, investment grade securities from diverse issuers. The valuation techniques used to measure the fair value of the Company’s marketable debt securities were derived from non-binding market consensus prices that are corroborated by observable market data and quoted market prices for similar instruments. The Company’s financial liabilities measured at fair value on a recurring basis consist of Level 1, Level 2 and Level 3 liabilities. The Company’s Public Warrants (as defined in Note 7) are classified as Level 1 because they are directly observable in the market. The Company classifies the Private Placement Warrants (as defined in Note 7) within Level 2, because they were valued using inputs other than quoted prices which are directly observable in the market, including readily available pricing for the Company’s Public Warrants. The Company classifies Delta Warrant and Earnout Shares Liability (as defined in Note 7) within Level 3, because they were valued using unobservable inputs that are significant to the fair value measurement. The Delta Warrant and Earnout Shares Liability are measured at fair value on a recurring basis. Changes in fair value of Level 3 liabilities are recorded in total other income (loss), net in the condensed consolidated statements of operations. The following tables set forth the fair value of the Company’s financial assets and liabilities measured on a recurring basis by level within the fair value hierarchy as of March 31, 2023 and December 31, 2022 (in thousands): March 31, 2023 Level 1 Level 2 Level 3 Total Assets measured at fair value Money market funds $ 16,016 $ — $ — $ 16,016 Cash equivalents $ 16,016 $ — $ — $ 16,016 Term deposits $ — $ 40,925 $ — $ 40,925 Asset backed securities — 54,250 — 54,250 Government debt securities — 444,229 — 444,229 Corporate debt securities — 388,576 — 388,576 Available-for-sale investments — 927,980 — 927,980 Total fair value of assets $ 16,016 $ 927,980 $ — $ 943,996 Liabilities measured at fair value Common stock warrant liabilities (Public) $ 11,213 $ — $ — $ 11,213 Common stock warrant liabilities (Private Placement) — 7,497 — 7,497 Common stock warrant liabilities (Delta) — — 19,104 19,104 Warrant liabilities 11,213 7,497 19,104 37,814 Earnout Shares Liability — — 57,094 57,094 Total fair value of liabilities $ 11,213 $ 7,497 $ 76,198 $ 94,908 December 31, 2022 Level 1 Level 2 Level 3 Total Assets measured at fair value Money market funds $ 108,119 $ — $ — $ 108,119 Cash equivalents $ 108,119 $ — $ — $ 108,119 Term deposits $ — $ 40,709 $ — $ 40,709 Asset backed securities — 54,707 — 54,707 Government debt securities — 362,851 — 362,851 Corporate debt securities — 452,425 — 452,425 Available-for-sale investments — 910,692 — 910,692 Total fair value of assets $ 108,119 $ 910,692 $ — $ 1,018,811 Liabilities measured at fair value Common stock warrant liabilities (Public) $ 8,318 $ — $ — $ 8,318 Common stock warrant liabilities (Private Placement) — 5,561 — 5,561 Common stock warrant liabilities (Delta) — — 14,903 14,903 Warrant liabilities 8,318 5,561 14,903 28,783 Earnout Shares Liability — — 44,055 44,055 Total fair value of liabilities $ 8,318 $ 5,561 $ 58,958 $ 72,838 The following is a summary of the Company’s available-for-sale securities (in thousands): March 31, 2023 Cost or Amortized Cost Unrealized Unrealized Allowance for credit losses Fair value Assets measured at fair value Term deposits $ 40,925 $ — $ — $ — $ 40,925 Asset backed securities 54,505 — (255) — 54,250 Government debt securities 446,660 196 (2,627) — 444,229 Corporate debt securities 390,857 19 (2,300) — 388,576 Total $ 932,947 $ 215 $ (5,182) $ — $ 927,980 December 31, 2022 Cost or Amortized Cost Unrealized Unrealized Allowance for credit losses Fair value Assets measured at fair value Term deposits $ 40,709 $ — $ — $ — $ 40,709 Asset backed securities 55,016 — (309) — 54,707 Government debt securities 367,324 — (4,473) — 362,851 Corporate debt securities 455,854 — (3,429) — 452,425 Total $ 918,903 $ — $ (8,211) $ — $ 910,692 There were no transfers between Level 1, Level 2 or Level 3 financial instruments in the three months ended March 31, 2023 and 2022. The following table sets forth a summary of the change in the fair value, which is recognized as a component of total other income (loss), net within the condensed consolidated statement of operations, of the Company’s Level 3 financial liabilities (in thousands): Earnout Shares Liability Common Stock Warrant Liabilities Delta Fair value as of January 1, 2023 $ 44,055 $ 14,903 Change in fair value 13,039 4,201 Fair value as of March 31, 2023 $ 57,094 $ 19,104

Acquisitions

Acquisitions	3 Months Ended
	Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Acquisitions	Acquisitions 2022 Acquisitions On March 9, 2022, the Company completed the acquisition of an aerospace composite manufacturing company, whereby it acquired all the purchased assets and assumed selected liabilities in exchange for a total consideration consisting of (i) $1.5 million in cash, and (ii) RSUs with the aggregate acquisition date value of $0.1 million. The acquisition was accounted for as a business combination as the assets acquired and liabilities assumed constituted a business in accordance with ASC 805 Business Combinations . The purchase consideration of $1.5 million was allocated to the following: a $1.1 million in favorable lease assets, $0.4 million of acquired machinery and equipment, $0.1 million of acquired current assets, and $0.1 million of acquired current liabilities. On May 17, 2022, the Company completed the acquisition of an aerospace software engineering company that specializes in full-lifecycle software and firmware development and verification to aviation regulatory standards, in exchange for total cash consideration of $7.2 million. The acquisition was accounted for as a business combination as the assets acquired and liabilities assumed constituted a business in accordance with ASC 805 Business Combinations . Part of the cash consideration in an amount of $2.2 million was temporarily retained by the Company to satisfy the Company’s post-closing indemnification claims, if any, against the seller. This retained amount is payable to the seller, net of indemnification claims, at the one-year anniversary of the acquisition. As of March 31, 2023, this retained amount of $2.2 million is presented as restricted cash on the Company’s condensed consolidated balance sheet, with a related corresponding amount in accrued and other liabilities, reflecting obligations to the seller. In relation to the acquisition, the Company issued 790,529 RSUs with an aggregate acquisition date value of approximately $4.5 million. The Company also paid $0.5 million to the employees of the acquired company, and settled accounts payable to the acquired company of $0.2 million. The RSUs vest contingent upon each employee’s continued employment with the Company or its subsidiaries, and are recognized as stock-based compensation expense over the RSUs’ vesting terms, commencing on the acquisition date. The purchase consideration of $7.2 million was, preliminarily, allocated to $3.3 million of goodwill, primarily resulting from the combined workforce and expected increased regulatory efficiencies, $2.5 million of total intangible assets comprising of $2.4 million of acquired customer relationships intangible asset and $0.1 million of acquired developed technology intangible asset, $1.5 million of acquired current assets, primarily consisting of cash and accounts receivable, $0.3 million of acquired fixed assets, and $0.4 million of acquired current liabilities. Amounts recognized as of the acquisition date are provisional and subject to change within the measurement period as the Company’s fair value assessments are finalized. In September 2022, the Company made certain measurement period adjustments, which included a working capital adjustment with the seller in accordance with the agreement terms, resulting in an increase to the purchase consideration of $0.1 million which was paid during the three months ended December 31, 2022.

Balance Sheet Components

Balance Sheet Components	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Balance Sheet Components	Balance Sheet Components Property and Equipment, Net Property and equipment, net consists of the following (in thousands): March 31, December 31, Equipment $ 67,485 $ 63,656 Buildings 21,384 21,384 Leasehold improvements 15,100 14,319 Computer software 11,598 10,920 Molds and tooling 10,793 10,298 Land 6,270 6,270 Vehicles and aircraft 1,597 1,582 Furniture and fixtures 690 682 Construction in-progress 6,465 6,094 Gross property and equipment 141,382 135,205 Accumulated depreciation and amortization (48,350) (43,102) Property and equipment, net $ 93,032 $ 92,103 Depreciation and amortization expense of property and equipment for the three months ended March 31, 2023 and 2022 was $5.5 million and $4.1 million, respectively. Vehicles and aircraft includes utility automobiles used at the Company’s various facilities and purchased aircraft to support the Company’s air operations and training. Intangible Assets, Net The intangible assets consist of the following (in thousands): March 31, December 31, Automation platform software $ 7,200 $ 7,200 Multimodal software technology 4,900 4,900 System simulation software technology 4,600 4,600 Other intangibles 5,328 5,328 Gross intangible assets 22,028 22,028 Accumulated amortization (10,943) (9,447) Intangible assets, net $ 11,085 $ 12,581 Amortization expense related to intangible assets for the three months ended March 31, 2023 and 2022 was $1.5 million and $1.1 million, respectively. As of March 31, 2023 the weighted-average amortization period of intangible assets was 2.1 years. The following table presents the estimated future amortization expense of acquired amortizable intangible assets as of March 31, 2023 (in thousands): Fiscal Year Amount 2023 (remainder) $ 4,537 2024 4,382 2025 2,166 $ 11,085 Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consist of the following (in thousands): March 31, December 31, Prepaid equipment $ 4,883 $ 4,525 Prepaid software 5,180 5,522 Prepaid taxes 2,048 1,273 Prepaid insurance 7,675 7,702 Other 2,432 1,138 Total $ 22,218 $ 20,160 Other non-current assets Other non-current assets consist of the following (in thousands): March 31, December 31, Contractual agreement asset $ 59,611 $ 59,611 Long term prepaid insurance 2,360 3,770 Other non-current assets 703 819 Total $ 62,674 $ 64,200 Accrued and other current liabilities Accrued and other current liabilities consist of the following (in thousands): March 31, December 31, Vendor related accruals $ 8,462 $ 7,508 Payroll accruals 9,778 5,992 Acquisition-related obligation accrual 2,167 2,167 Other accruals and current liabilities 2,437 3,116 Total $ 22,844 $ 18,783

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Contingencies The Company is subject to claims and assessments from time to time in the ordinary course of business. Accruals for litigation and contingencies are reflected in the Condensed Consolidated Financial Statements based on management’s assessment, including the advice of legal counsel, of the expected outcome of litigation or other dispute resolution proceedings and/or the expected resolution of contingencies. Liabilities for estimated losses are accrued if the potential losses from any claims or legal proceedings are considered probable and the amounts can be reasonably estimated. Significant judgment is required in both the determination of probability of loss and the determination as to whether the amount can be reasonably estimated. Accruals are based only on information available at the time of the assessment due to the uncertain nature of such matters. As additional information becomes available, management reassesses potential liabilities related to pending claims and litigation and may revise its previous estimates, which could materially affect the Company’s condensed consolidated results of operations in a given period. As of March 31, 2023, and December 31, 2022, the Company was not involved in any material legal proceedings. Indemnifications In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnifications. The Company’s exposure under these agreements

Stock Warrants and Earnout Shar

Stock Warrants and Earnout Shares	3 Months Ended
	Mar. 31, 2023
Warrants and Rights Note Disclosure [Abstract]
Stock Warrants and Earnout Shares	Stock Warrants and Earnout Shares Private Placement and Public Warrants In connection with the Merger, each of the 17,250,000 publicly-traded warrants (“Public Warrants”) and 11,533,333 private placement warrants (“Private Placement Warrants” and, together with the Public Warrants, the “Common Stock Warrants”) issued to Reinvent Sponsor, LLC (the “Sponsor”) in connection with RTP’s initial public offering and subsequent overallotment were converted into an equal number of warrants that entitle the holder to purchase one share of the Company’s Common stock, par value $0.0001 (“Common Stock”) at an exercise price of $11.50 per share, subject to adjustments, and will expire five years after the completion of the Merger or earlier upon redemption or the Company’s liquidation. Once the Common Stock Warrants become exercisable, the Company may redeem the outstanding Common Stock Warrants subject to certain Common Stock price and other conditions as defined in the Warrant Agreement between RTP and Continental Stock Transfer & Trust Company (“Warrant Agreement”) and the Sponsor Agreement by and among the Company, Sponsor and RTP (“Sponsor Agreement”). During the three months ended March 31, 2023, no Common Stock Warrants were exercised. The Private Placement Warrants were initially recognized as a liability on August 10, 2021, at a fair value of $21.9 million. For the three months ended March 31, 2023 and 2022, the Private Placement Warrant liability was remeasured to fair value as of March 31, 2023 and 2022, resulting in losses of $1.9 million and $1.0 million, respectively, which is included within the gain (loss) from change in the fair value of warrants and earnout shares in the condensed consolidated statements of operations. The Public Warrants were initially recognized as a liability on August 10, 2021 at a fair value of $32.8 million. For the three months ended March 31, 2023 and 2022, the public warrant liability was remeasured to fair value based upon the market price as of March 31, 2023 and 2022, resulting in losses of $2.9 million and $1.6 million, respectively, classified within the gain (loss) from change in the fair value of warrants and earnout shares in the condensed consolidated statements of operations. Earnout Shares Liability In connection with the Reverse Recapitalization and pursuant to the Sponsor Agreement, Sponsor agreed to certain terms of vesting, lock-up and transfer with respect to the 17,130,000 common shares held by it (“Earnout Shares”). The terms of the Sponsor Agreement specify that the Earnout Shares will vest upon achieving certain specified release events. In accordance with ASC 815 Derivatives and Hedging , the Earnout Shares are not indexed to the Common Stock and therefore are accounted for as a liability (“Earnout Shares Liability”) as of the Closing Date and subsequently remeasured at each reporting date with changes in fair value recorded as a component of total other income (loss), net in the condensed consolidated statements of operations. Under the vesting schedule, 20% of the Earnout Shares vest in tranches when the volume-weighted average price of the Company’s common stock quoted on the NYSE is greater than $12.00, $18.00, $24.00, $32.00 and $50.00 for any 20 trading days within a period of 30 trading days (each such occurrence a “Triggering Event”). After ten years following the consummation of the Merger (the “Earnout Period”), any Earnout Shares which have not yet vested are forfeited. No Earnout Shares vested as of March 31, 2023. Earnout Shares Liability at the closing of the Merger on August 10, 2021, was $149.9 million based on a Monte Carlo simulation valuation model using a distribution of potential outcomes on a monthly basis over the Earnout Period using the most reliable information available. During the three months ended March 31, 2023 and 2022, the Company recognized a loss related to the change in the fair value of the Earnout Shares Liability of $13.0 million and a gain of $19.4 million, respectively, included within the gain (loss) from change in fair value of warrants and earnout shares in the condensed consolidated statement of operations. Assumptions used in the valuation are as follows: March 31, 2023 December 31, 2022 Expected volatility 70.60 % 73.70 % Risk-free interest rate 3.52 % 3.92 % Dividend rate 0.00 % 0.00 % Expected term (years) 8.36 8.61 Delta Warrant In connection with the umbrella agreement that the Company entered with Delta Air Lines, Inc. (“Delta”) on October 7, 2022, the Company sold and issued to Delta, in private placement, 11,044,232 shares of the Company’s Common Stock, at the per-share purchase price of $5.4327, for an aggregate cash consideration of $60.0 million. In addition, the Company issued a warrant for Delta to purchase up to 12,833,333 shares of the Company's common stock in two tranches, subject to certain milestone achievement conditions (“Delta Warrant”). The first and the second tranches of the warrant permit Delta to purchase up to 7,000,000 and 5,833,333 shares of Common Stock at exercise prices of $10 and $12, respectively, starting from the date the applicable milestones are satisfied and ending on the ten year anniversary of the warrant issuance date. The number of shares and exercise price for both tranches is subject to value cap adjustment if the 30 day volume weighted average price per share of the Company’s stock exceeds 150% of each respective tranche’s exercise price, but disregarding any price increases occurring within 10 business days after a public announcement of the achievement of an applicable milestone, if any. The Company concluded that no assets or liabilities were transferred by either party beyond the Company’s issuance of common stock and warrants in exchange for the total cash consideration from Delta, that the umbrella agreement does not constitute a funded research and development agreement in the scope of ASC 730 “Research and Development” or a collaborative agreement in the scope of ASC 808 “Collaborative Agreements”, and that the Delta Warrant is a freestanding financial instrument not indexed to the Company’s own stock. Accordingly, the Company recognized the issuance of Common Stock as equity in additional paid-in capital on condensed consolidated balance sheets and the Delta Warrant as liability on the condensed consolidated balance sheets at fair value. The Delta Warrant issuance was initially recognized as a liability on October 7, 2022, at a fair value of $16.1 million based on a Monte Carlo simulation valuation model using the most reliable information available. The Delta Warrant’s liability was remeasured to fair value as of March 31, 2023, resulting in a loss of $4.2 million, which is included within the gain (loss) from change in the fair value of warrants and earnout shares in the condensed consolidated statements of operations Assumptions used in the valuation of Delta Warrants are as follows: March 31, 2023 December 31, 2022 Expected volatility 78.40 % 75.10 % Risk-free interest rate 3.49 % 3.89 % Dividend rate — % — % Expected term (in years) 9.5 9.8

Stock-Based Compensation

Stock-Based Compensation	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	Stock-based Compensation Equity Compensation Plans In November 2016, the Company’s Board of Directors adopted the 2016 Stock Option and Grant Plan (“2016 Plan”) under which officers, employees, directors, consultants and other key persons of the Company or its affiliates may be granted incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock and restricted stock units. On August 10, 2021, the Company’s Board of Directors amended the 2016 Plan to provide that no new awards could be granted under the 2016 Plan. Under the 2016 Plan, stock options are generally granted with an exercise price equal to the estimated fair value of the Company’s common stock, as determined by the Company’s Board of Directors on the date of grant. Options generally have contractual terms of ten years. Incentive stock options (ISO) may only be granted to employees, whereas all other stock awards may be granted to employees, directors, consultants and other key persons. Outstanding options generally vest over six years, contain a one year cliff, are exercisable immediately and, upon early exercise, are subject to repurchase by the Company at the original exercise price. If an ISO is granted to an optionee who, at the time of grant, owns more than 10% of the voting power of all classes of capital stock, the term of the ISO is five years. Options issued under the 2016 Plan must be priced at no less than the fair value of the shares on the date of the grant provided, however, that the exercise price of an option granted to a 10% stockholder is not less than 110% of the fair value of the shares on the date of grant. The Board of Directors determines the exercisability provisions of a stock option agreement at its sole discretion. On August 10, 2021, the Company adopted the 2021 Equity Incentive Plan (“2021 Plan”). Under the 2021 Plan, the Company can grant incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units and performance awards to employees, directors and consultants. The number of shares available for issuance under the 2021 Plan will be increased on the first day of each fiscal year, beginning on January 1, 2022, in an amount equal to the lesser of (i) a number of shares equal to four percent (4%) of the total number of shares of all classes of common stock of the Company outstanding on the last day of the immediately preceding fiscal year, or (ii) such number of shares determined by the Company’s Board of Directors. On January 1, 2023, the number of shares available for issuance under 2021 plan increased by 24,904,113 shares. Restricted Stock Units The summary of RSU activity is as follows (in thousands, except per share data): Number of Units Weighted-Average Grant Date Fair Value Per Share Aggregate Intrinsic Value (in thousands) Balances—December 31, 2022 28,537,127 $ 5.75 $ 95,599 Granted 1,973,570 $ 3.84 Vested (5,839,302) $ 4.58 Forfeited (815,705) $ 6.32 Balances—March 31, 2023 23,855,690 $ 5.86 $ 103,534 On December 16, 2021, the Company’s Board of Directors approved a performance-based bonus program under which RSUs were awarded in connection with the achievement of specified goals to be achieved in 2022 (“2022 Bonus Plan”). The RSUs awarded under 2022 Bonus Plan vested on January 1, 2023 and are included in Restricted Stock Units activity for the three months ended March 31, 2023. On February 27, 2023, the Company’s Compensation Committee of the Board of Directors ("Compensation Committee") approved a performance-based bonus program under which RSUs will be awarded in connection with the achievement of specified goals in 2023 ("2023 Bonus Plan"). The RSU awards will be granted when the achievement of each goal is approved by the Compensation Committee in 2023, and the RSUs will vest in equal installments in each of January, February, March and April 2024 provided the employee or consultant continues to be a service provider through the relevant vesting dates. The target bonus opportunity is equal to 30% of the employee’s base salary as of the applicable grant date, with stretch bonus goals that are one-third higher than the target amounts unless otherwise established by the Compensation Committee. The Company recorded stock-based compensation expense of $3.3 million and $7.3 million during the three months ended March 31, 2023 and 2022 in relation to 2023 Bonus Plan and 2022 Bonus Plan, respectively. The Company considers the probability of achieving each of the performance goals at the end of each reporting period and recognizes expense over the requisite service period when achievement of the goal is determined to be probable, and adjusts the expense if the probability of achieving the goal later changes. In accordance with ASC 718 Compensation - Stock Compensation , awards under 2023 Bonus Plan and 2022 Bonus Plan are classified as a liability until such time that the respective milestones are met, at which point the liability is reclassified to equity. If it is determined that the milestone cannot be met, the liability will be reversed. Employee Stock Purchase Plan On August 10, 2021, the Company adopted the 2021 Employee Stock Purchase Plan (“2021 ESPP”). Under the 2021 ESPP, participating employees may be offered the option to purchase shares of the Company’s Common Stock at a purchase price which equals 85% of the fair market value of the Company’s common stock on the enrollment date or on the exercise date, whichever is lower. The number of shares of common stock available for issuance under the 2021 ESPP will be increased on the first day of each fiscal year beginning on January 1, 2022, in an amount equal to the lesser of (i) a number of shares of common stock equal to half percent (0.5%) of the total number of shares of all classes of common stock of the Company on the last day of the immediately preceding fiscal year, or (ii) such number of shares determined by the Company’s Board of Directors. On January 1, 2023, the number of shares available for issuance under 2021 ESPP increased by 3,113,014 shares. The 2021 ESPP’s first offering and purchase periods began in November 2022 with the first purchase period ending in May 2023. Accordingly, as of March 31, 2023, no shares have been issued under the 2021 ESPP. The stock-based compensation expense recognized for the 2021 ESPP was $0.8 million and nil for the three months ended March 31, 2023 and 2022, respectively. Stock-based Compensation Expense The following sets forth the total stock-based compensation expense included in the Company’s condensed consolidated statements of operations (in thousands): Three Months Ended March 31, 2023 2022 Research and development expenses $ 13,044 $ 14,722 Selling, general and administrative expenses 4,214 4,707 Total stock-based compensation expense $ 17,258 $ 19,429 Shares subject to repurchase The Company allows certain option holders to exercise unvested options to purchase shares of common stock. Common shares received from such early exercises are subject to a right of repurchase at the original issuance price. The Company’s repurchase right with respect to these shares lapses as the shares vest. These awards are typically subject to a vesting period of six years. As of March 31, 2023 and December 31, 2022, 3,338,985 and 3,923,509 shares, respectively, were subject to repurchase at a weighted average price of $0.10 per share and $0.10 per share, respectively, and $0.3 million and $0.4 million, respectively, was recorded within the other non-current liabilities on the Company’s condensed consolidated balance sheets. In addition, upon completion of the Reverse Recapitalization 2,677,200 Series C Preferred shares which were subject to time-based vesting conditions were converted to restricted common shares. As of March 31, 2023 and December 31, 2022, the number of such shares that were subject to repurchase was 1,895,180 and 2,007,595, respectively.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions The Company’s Chief Executive Officer and founder has ownership interests in certain vendors providing services to the Company. The services purchased from these vendors include rent of office space and certain utilities and maintenance services related to the property on which the rented premises are located. Expenses and related payments to these vendors totaled $0.2 million and $0.2 million during the three months ended March 31, 2023 and 2022, respectively. In addition, the Company entered into certain transactions with SummerBio in the year ended December 31, 2022. These transactions included purchases of COVID-19 testing services for the Company’s employees and certain assets for a total amount of $0.6 million during the three months ended March 31, 2022.

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Common Stockholders	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Net Loss per Share Attributable to Common Stockholders	Net Loss per Share Attributable to Common Stockholders Basic net loss per share is computed by dividing the net loss by the weighted-average number of common shares outstanding for the period. Because the Company reported a net loss for the three months ended March 31, 2023 and 2022, the number of shares used to calculate diluted net loss per common share is the same as the number of shares used to calculate basic net loss per common share for those periods presented because the potentially dilutive shares would have been antidilutive if included in the calculation. The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data): Three Months Ended 2023 2022 Numerator: Net loss attributable to common stockholders $ (113,393) $ (62,319) Denominator: Weighted-average shares outstanding 605,184,671 579,090,606 Net loss per share attributable to common stockholders, basic and diluted $ (0.19) $ (0.11) The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: March 31, 2023 Common stock warrants 28,783,333 Unvested restricted stock units 23,855,690 Options to purchase common stock and unvested restricted stock awards 17,782,326 Unvested early exercised common stock options 3,338,985 Total 73,760,334 March 31, 2022 Common stock warrants 28,783,333 Unvested restricted stock units 18,964,922 Options to purchase common stock and unvested restricted stock awards 22,622,456 Unvested early exercised common stock options 6,266,063 Earnout Shares 17,130,000 Total 93,766,774

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events The Company evaluated subsequent events and transactions that occurred up to the date financial statements were issued. On May 3, 2023, the Company entered into a common stock purchase agreement with certain institutional investors for the issuance and sale in a registered direct offering of 43,985,681 shares of the Company's common stock, par value $0.0001 per share, at an offering price of $4.10 per share. The offering is expected to close on or about May 5, 2023. The net proceeds from the offering were approximately $180.2 million, after deducting estimated offering expenses payable by the Company. The offering was made pursuant to the Company's effective shelf registration statement on Form S-3 previously filed with and declared effective by the Securities and Exchange Commission (the “SEC”) and a prospectus supplement and accompanying prospectus filed with the SEC.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Condensed Consolidated Financial Statements are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and include all adjustments necessary for the fair presentation of the Company’s financial position, results of operations and cash flows for the periods presented. The Condensed Consolidated Financial Statements include accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
Cash, Cash Equivalents, and Restricted Cash	Cash, Cash Equivalents, and Restricted Cash The Company considers all highly liquid investments with remaining original maturity of three months or less, from the date of purchase, to be cash and cash equivalents. The recorded carrying amount of cash and cash equivalents approximates their fair value.
Investment in SummerBio, LLC	Investment in SummerBio, LLC Following the outbreak of the COVID-19 pandemic, the Company’s management determined that certain previously developed technology that was accessible to the Company could be repurposed and applied in providing high-volume rapid COVID-19 testing through its investment in SummerBio, LLC (“SummerBio”), a related party. The Company has determined that it is not the primary beneficiary of SummerBio. Therefore, it accounts for its investment in SummerBio under the equity method of accounting
New Accounting Pronouncements Not Yet Adopted	New Accounting Pronouncements Not Yet Adopted There are no recent accounting pronouncements applicable to the Company pending adoption that the Company expects will have a material impact on our condensed consolidated financial condition, results of operations, or cash flows.
Fair Value Measurements	A financial instrument’s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The Company’s financial assets consist of Level 1 and 2 assets. The Company classifies its cash equivalents and marketable debt securities within Level 1 or Level 2 because they are valued using either quoted market prices or inputs other than quoted prices which are directly or indirectly observable in the market, including readily-available pricing sources for the identical underlying security which may not be actively traded. The Company’s fixed income available-for-sale securities consist of high quality, investment grade securities from diverse issuers. The valuation techniques used to measure the fair value of the Company’s marketable debt securities were derived from non-binding market consensus prices that are corroborated by observable market data and quoted market prices for similar instruments.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following tables set forth the fair value of the Company’s financial assets and liabilities measured on a recurring basis by level within the fair value hierarchy as of March 31, 2023 and December 31, 2022 (in thousands): March 31, 2023 Level 1 Level 2 Level 3 Total Assets measured at fair value Money market funds $ 16,016 $ — $ — $ 16,016 Cash equivalents $ 16,016 $ — $ — $ 16,016 Term deposits $ — $ 40,925 $ — $ 40,925 Asset backed securities — 54,250 — 54,250 Government debt securities — 444,229 — 444,229 Corporate debt securities — 388,576 — 388,576 Available-for-sale investments — 927,980 — 927,980 Total fair value of assets $ 16,016 $ 927,980 $ — $ 943,996 Liabilities measured at fair value Common stock warrant liabilities (Public) $ 11,213 $ — $ — $ 11,213 Common stock warrant liabilities (Private Placement) — 7,497 — 7,497 Common stock warrant liabilities (Delta) — — 19,104 19,104 Warrant liabilities 11,213 7,497 19,104 37,814 Earnout Shares Liability — — 57,094 57,094 Total fair value of liabilities $ 11,213 $ 7,497 $ 76,198 $ 94,908 December 31, 2022 Level 1 Level 2 Level 3 Total Assets measured at fair value Money market funds $ 108,119 $ — $ — $ 108,119 Cash equivalents $ 108,119 $ — $ — $ 108,119 Term deposits $ — $ 40,709 $ — $ 40,709 Asset backed securities — 54,707 — 54,707 Government debt securities — 362,851 — 362,851 Corporate debt securities — 452,425 — 452,425 Available-for-sale investments — 910,692 — 910,692 Total fair value of assets $ 108,119 $ 910,692 $ — $ 1,018,811 Liabilities measured at fair value Common stock warrant liabilities (Public) $ 8,318 $ — $ — $ 8,318 Common stock warrant liabilities (Private Placement) — 5,561 — 5,561 Common stock warrant liabilities (Delta) — — 14,903 14,903 Warrant liabilities 8,318 5,561 14,903 28,783 Earnout Shares Liability — — 44,055 44,055 Total fair value of liabilities $ 8,318 $ 5,561 $ 58,958 $ 72,838
Summary of Debt Securities, Available-for-sale	The following is a summary of the Company’s available-for-sale securities (in thousands): March 31, 2023 Cost or Amortized Cost Unrealized Unrealized Allowance for credit losses Fair value Assets measured at fair value Term deposits $ 40,925 $ — $ — $ — $ 40,925 Asset backed securities 54,505 — (255) — 54,250 Government debt securities 446,660 196 (2,627) — 444,229 Corporate debt securities 390,857 19 (2,300) — 388,576 Total $ 932,947 $ 215 $ (5,182) $ — $ 927,980 December 31, 2022 Cost or Amortized Cost Unrealized Unrealized Allowance for credit losses Fair value Assets measured at fair value Term deposits $ 40,709 $ — $ — $ — $ 40,709 Asset backed securities 55,016 — (309) — 54,707 Government debt securities 367,324 — (4,473) — 362,851 Corporate debt securities 455,854 — (3,429) — 452,425 Total $ 918,903 $ — $ (8,211) $ — $ 910,692
Summary of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following table sets forth a summary of the change in the fair value, which is recognized as a component of total other income (loss), net within the condensed consolidated statement of operations, of the Company’s Level 3 financial liabilities (in thousands): Earnout Shares Liability Common Stock Warrant Liabilities Delta Fair value as of January 1, 2023 $ 44,055 $ 14,903 Change in fair value 13,039 4,201 Fair value as of March 31, 2023 $ 57,094 $ 19,104

Balance Sheet Components (Table

Balance Sheet Components (Tables)	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Summary of Property, Plant and Equipment	Property and equipment, net consists of the following (in thousands): March 31, December 31, Equipment $ 67,485 $ 63,656 Buildings 21,384 21,384 Leasehold improvements 15,100 14,319 Computer software 11,598 10,920 Molds and tooling 10,793 10,298 Land 6,270 6,270 Vehicles and aircraft 1,597 1,582 Furniture and fixtures 690 682 Construction in-progress 6,465 6,094 Gross property and equipment 141,382 135,205 Accumulated depreciation and amortization (48,350) (43,102) Property and equipment, net $ 93,032 $ 92,103
Schedule of Intangible Assets	The intangible assets consist of the following (in thousands): March 31, December 31, Automation platform software $ 7,200 $ 7,200 Multimodal software technology 4,900 4,900 System simulation software technology 4,600 4,600 Other intangibles 5,328 5,328 Gross intangible assets 22,028 22,028 Accumulated amortization (10,943) (9,447) Intangible assets, net $ 11,085 $ 12,581
Schedule of Estimated Future Amortization Expense of Acquired Intangible Assets	The following table presents the estimated future amortization expense of acquired amortizable intangible assets as of March 31, 2023 (in thousands): Fiscal Year Amount 2023 (remainder) $ 4,537 2024 4,382 2025 2,166 $ 11,085
Schedule of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consist of the following (in thousands): March 31, December 31, Prepaid equipment $ 4,883 $ 4,525 Prepaid software 5,180 5,522 Prepaid taxes 2,048 1,273 Prepaid insurance 7,675 7,702 Other 2,432 1,138 Total $ 22,218 $ 20,160
Schedule of Other Noncurrent Assets	Other non-current assets consist of the following (in thousands): March 31, December 31, Contractual agreement asset $ 59,611 $ 59,611 Long term prepaid insurance 2,360 3,770 Other non-current assets 703 819 Total $ 62,674 $ 64,200
Schedule of Accrued and Other Liabilities	Accrued and other current liabilities consist of the following (in thousands): March 31, December 31, Vendor related accruals $ 8,462 $ 7,508 Payroll accruals 9,778 5,992 Acquisition-related obligation accrual 2,167 2,167 Other accruals and current liabilities 2,437 3,116 Total $ 22,844 $ 18,783

Stock Warrants and Earnout Sh_2

Stock Warrants and Earnout Shares (Tables)	3 Months Ended
	Mar. 31, 2023
Warrants and Rights Note Disclosure [Abstract]
Schedule of Assumptions Used to Estimate Fair Value of The Total Earnout Shares Liability	Assumptions used in the valuation are as follows: March 31, 2023 December 31, 2022 Expected volatility 70.60 % 73.70 % Risk-free interest rate 3.52 % 3.92 % Dividend rate 0.00 % 0.00 % Expected term (years) 8.36 8.61 Assumptions used in the valuation of Delta Warrants are as follows: March 31, 2023 December 31, 2022 Expected volatility 78.40 % 75.10 % Risk-free interest rate 3.49 % 3.89 % Dividend rate — % — % Expected term (in years) 9.5 9.8

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Nonvested Restricted Stock Units Activity	The summary of RSU activity is as follows (in thousands, except per share data): Number of Units Weighted-Average Grant Date Fair Value Per Share Aggregate Intrinsic Value (in thousands) Balances—December 31, 2022 28,537,127 $ 5.75 $ 95,599 Granted 1,973,570 $ 3.84 Vested (5,839,302) $ 4.58 Forfeited (815,705) $ 6.32 Balances—March 31, 2023 23,855,690 $ 5.86 $ 103,534
Summary of stock-based compensation expense	The following sets forth the total stock-based compensation expense included in the Company’s condensed consolidated statements of operations (in thousands): Three Months Ended March 31, 2023 2022 Research and development expenses $ 13,044 $ 14,722 Selling, general and administrative expenses 4,214 4,707 Total stock-based compensation expense $ 17,258 $ 19,429

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Common Stockholders (Tables)	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders	The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data): Three Months Ended 2023 2022 Numerator: Net loss attributable to common stockholders $ (113,393) $ (62,319) Denominator: Weighted-average shares outstanding 605,184,671 579,090,606 Net loss per share attributable to common stockholders, basic and diluted $ (0.19) $ (0.11)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: March 31, 2023 Common stock warrants 28,783,333 Unvested restricted stock units 23,855,690 Options to purchase common stock and unvested restricted stock awards 17,782,326 Unvested early exercised common stock options 3,338,985 Total 73,760,334 March 31, 2022 Common stock warrants 28,783,333 Unvested restricted stock units 18,964,922 Options to purchase common stock and unvested restricted stock awards 22,622,456 Unvested early exercised common stock options 6,266,063 Earnout Shares 17,130,000 Total 93,766,774

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Summary Of Significant Accounting Policies [Line Items]
Restricted cash	$ 2,997	$ 1,731
Income from equity method investment	$ 0	$ 14,458
SummerBio
Summary Of Significant Accounting Policies [Line Items]
Ownership interest	44.50%		44.50%
Letter of Credit
Summary Of Significant Accounting Policies [Line Items]
Restricted cash	$ 1,000
Lease Obligation
Summary Of Significant Accounting Policies [Line Items]
Restricted cash	800
Acquired Current Liabilities
Summary Of Significant Accounting Policies [Line Items]
Restricted cash	$ 2,200

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Assets measured at fair value
Fair value	$ 927,980	$ 910,692
Liabilities measured at fair value
Warrant liabilities	37,814	28,783
Earnout Shares Liability	57,094	44,055
Term deposits
Assets measured at fair value
Fair value	40,925	40,709
Asset backed securities
Assets measured at fair value
Fair value	54,250	54,707
Government debt securities
Assets measured at fair value
Fair value	444,229	362,851
Corporate debt securities
Assets measured at fair value
Fair value	388,576	452,425
Fair Value Measurements Recurring
Assets measured at fair value
Cash equivalents	16,016	108,119
Fair value	927,980	910,692
Total fair value of assets	943,996	1,018,811
Liabilities measured at fair value
Warrant liabilities	37,814	28,783
Earnout Shares Liability	57,094	44,055
Total fair value of liabilities	94,908	72,838
Fair Value Measurements Recurring | Common stock warrant liabilities (Public)
Liabilities measured at fair value
Warrant liabilities	11,213	8,318
Fair Value Measurements Recurring | Common stock warrant liabilities (Private Placement)
Liabilities measured at fair value
Warrant liabilities	7,497	5,561
Fair Value Measurements Recurring | Common stock warrant liabilities (Delta)
Liabilities measured at fair value
Warrant liabilities	19,104	14,903
Fair Value Measurements Recurring | Money market funds
Assets measured at fair value
Cash equivalents	16,016	108,119
Fair Value Measurements Recurring | Term deposits
Assets measured at fair value
Fair value	40,925	40,709
Fair Value Measurements Recurring | Asset backed securities
Assets measured at fair value
Fair value	54,250	54,707
Fair Value Measurements Recurring | Government debt securities
Assets measured at fair value
Fair value	444,229	362,851
Fair Value Measurements Recurring | Corporate debt securities
Assets measured at fair value
Fair value	388,576	452,425
Fair Value Measurements Recurring | Level 1
Assets measured at fair value
Cash equivalents	16,016	108,119
Fair value	0	0
Total fair value of assets	16,016	108,119
Liabilities measured at fair value
Warrant liabilities	11,213	8,318
Earnout Shares Liability	0	0
Total fair value of liabilities	11,213	8,318
Fair Value Measurements Recurring | Level 1 | Common stock warrant liabilities (Public)
Liabilities measured at fair value
Warrant liabilities	11,213	8,318
Fair Value Measurements Recurring | Level 1 | Common stock warrant liabilities (Private Placement)
Liabilities measured at fair value
Warrant liabilities	0	0
Fair Value Measurements Recurring | Level 1 | Common stock warrant liabilities (Delta)
Liabilities measured at fair value
Warrant liabilities	0	0
Fair Value Measurements Recurring | Level 1 | Money market funds
Assets measured at fair value
Cash equivalents	16,016	108,119
Fair Value Measurements Recurring | Level 1 | Term deposits
Assets measured at fair value
Fair value	0	0
Fair Value Measurements Recurring | Level 1 | Asset backed securities
Assets measured at fair value
Fair value	0	0
Fair Value Measurements Recurring | Level 1 | Government debt securities
Assets measured at fair value
Fair value	0	0
Fair Value Measurements Recurring | Level 1 | Corporate debt securities
Assets measured at fair value
Fair value	0	0
Fair Value Measurements Recurring | Level 2
Assets measured at fair value
Cash equivalents	0	0
Fair value	927,980	910,692
Total fair value of assets	927,980	910,692
Liabilities measured at fair value
Warrant liabilities	7,497	5,561
Earnout Shares Liability	0	0
Total fair value of liabilities	7,497	5,561
Fair Value Measurements Recurring | Level 2 | Common stock warrant liabilities (Public)
Liabilities measured at fair value
Warrant liabilities	0	0
Fair Value Measurements Recurring | Level 2 | Common stock warrant liabilities (Private Placement)
Liabilities measured at fair value
Warrant liabilities	7,497	5,561
Fair Value Measurements Recurring | Level 2 | Common stock warrant liabilities (Delta)
Liabilities measured at fair value
Warrant liabilities	0	0
Fair Value Measurements Recurring | Level 2 | Money market funds
Assets measured at fair value
Cash equivalents	0	0
Fair Value Measurements Recurring | Level 2 | Term deposits
Assets measured at fair value
Fair value	40,925	40,709
Fair Value Measurements Recurring | Level 2 | Asset backed securities
Assets measured at fair value
Fair value	54,250	54,707
Fair Value Measurements Recurring | Level 2 | Government debt securities
Assets measured at fair value
Fair value	444,229	362,851
Fair Value Measurements Recurring | Level 2 | Corporate debt securities
Assets measured at fair value
Fair value	388,576	452,425
Fair Value Measurements Recurring | Level 3
Assets measured at fair value
Cash equivalents	0	0
Fair value	0	0
Total fair value of assets	0	0
Liabilities measured at fair value
Warrant liabilities	19,104	14,903
Earnout Shares Liability	57,094	44,055
Total fair value of liabilities	76,198	58,958
Fair Value Measurements Recurring | Level 3 | Common stock warrant liabilities (Public)
Liabilities measured at fair value
Warrant liabilities	0	0
Fair Value Measurements Recurring | Level 3 | Common stock warrant liabilities (Private Placement)
Liabilities measured at fair value
Warrant liabilities	0	0
Fair Value Measurements Recurring | Level 3 | Common stock warrant liabilities (Delta)
Liabilities measured at fair value
Warrant liabilities	19,104	14,903
Fair Value Measurements Recurring | Level 3 | Money market funds
Assets measured at fair value
Cash equivalents	0	0
Fair Value Measurements Recurring | Level 3 | Term deposits
Assets measured at fair value
Fair value	0	0
Fair Value Measurements Recurring | Level 3 | Asset backed securities
Assets measured at fair value
Fair value	0	0
Fair Value Measurements Recurring | Level 3 | Government debt securities
Assets measured at fair value
Fair value	0	0
Fair Value Measurements Recurring | Level 3 | Corporate debt securities
Assets measured at fair value
Fair value	$ 0	$ 0

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Debt Securities, Available-for-sale (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Cost or Amortized Cost	$ 932,947	$ 918,903
Unrealized Gains	215	0
Unrealized Losses	(5,182)	(8,211)
Allowance for credit losses	0	0
Fair value	927,980	910,692
Term deposits
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Cost or Amortized Cost	40,925	40,709
Unrealized Gains	0	0
Unrealized Losses	0	0
Allowance for credit losses	0	0
Fair value	40,925	40,709
Asset backed securities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Cost or Amortized Cost	54,505	55,016
Unrealized Gains	0	0
Unrealized Losses	(255)	(309)
Allowance for credit losses	0	0
Fair value	54,250	54,707
Government debt securities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Cost or Amortized Cost	446,660	367,324
Unrealized Gains	196	0
Unrealized Losses	(2,627)	(4,473)
Allowance for credit losses	0	0
Fair value	444,229	362,851
Corporate debt securities
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Cost or Amortized Cost	390,857	455,854
Unrealized Gains	19	0
Unrealized Losses	(2,300)	(3,429)
Allowance for credit losses	0	0
Fair value	$ 388,576	$ 452,425

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2023 USD ($)
Earnout Shares
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 44,055
Change in fair value	13,039
Ending balance	57,094
Common stock warrant liabilities (Delta)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	14,903
Change in fair value	4,201
Ending balance	$ 19,104

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Liability [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net	$ 0	$ 0

Acquisitions - Business Combina

Acquisitions - Business Combinations Narrative (Details) - USD ($) $ in Thousands			1 Months Ended	3 Months Ended
	May 17, 2022	Mar. 09, 2022	Sep. 30, 2022	Mar. 31, 2023	Dec. 31, 2022
Business Acquisition [Line Items]
Restricted cash				$ 2,235	$ 3,204
Goodwill				14,011	14,011
Unvested restricted stock units
Business Acquisition [Line Items]
Aggregate Intrinsic Value				$ 103,534	$ 95,599
Awards Granted (in shares)				1,973,570
Aerospace Composites Manufacturing Entity
Business Acquisition [Line Items]
Cash payments		$ 1,500
Total purchase consideration		1,500
Finite-lived intangible assets		1,100
Acquired machinery and equipment		400
Acquired current assets		100
Acquired current liabilities		100
Aerospace Composites Manufacturing Entity | Off-Market Favorable Lease
Business Acquisition [Line Items]
Finite-lived intangible assets		1,100
Aerospace Composites Manufacturing Entity | Unvested restricted stock units
Business Acquisition [Line Items]
Aggregate Intrinsic Value		$ 100
Aerospace Software Engineering Entity
Business Acquisition [Line Items]
Cash payments	$ 7,200
Total purchase consideration	7,200
Finite-lived intangible assets	2,500
Acquired machinery and equipment	300
Acquired current assets	1,500
Acquired current liabilities	400
Restricted cash	2,200			$ 2,200
Payment to employees	500
Settlement of accounts payable	200
Goodwill	3,300
Increase to purchase consideration			$ 100
Aerospace Software Engineering Entity | Customer Relationships
Business Acquisition [Line Items]
Finite-lived intangible assets	2,400
Aerospace Software Engineering Entity | Developed Technology Rights
Business Acquisition [Line Items]
Finite-lived intangible assets	100
Aerospace Software Engineering Entity | Unvested restricted stock units
Business Acquisition [Line Items]
Aggregate Intrinsic Value	$ 4,500
Awards Granted (in shares)	790,529

Balance sheet Components - Summ

Balance sheet Components - Summary of Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Property Plant And Equipment [Line Items]
Gross property and equipment	$ 141,382	$ 135,205
Accumulated depreciation and amortization	(48,350)	(43,102)
Property and equipment, net	93,032	92,103
Equipment
Property Plant And Equipment [Line Items]
Gross property and equipment	67,485	63,656
Buildings
Property Plant And Equipment [Line Items]
Gross property and equipment	21,384	21,384
Leasehold improvements
Property Plant And Equipment [Line Items]
Gross property and equipment	15,100	14,319
Computer software
Property Plant And Equipment [Line Items]
Gross property and equipment	11,598	10,920
Molds and tooling
Property Plant And Equipment [Line Items]
Gross property and equipment	10,793	10,298
Land
Property Plant And Equipment [Line Items]
Gross property and equipment	6,270	6,270
Vehicles and aircraft
Property Plant And Equipment [Line Items]
Gross property and equipment	1,597	1,582
Furniture and fixtures
Property Plant And Equipment [Line Items]
Gross property and equipment	690	682
Construction in-progress
Property Plant And Equipment [Line Items]
Gross property and equipment	$ 6,465	$ 6,094

Balance sheet Components - Addi

Balance sheet Components - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Depreciation and amortization expense	$ 5.5	$ 4.1
Amortization of Intangible Assets	$ 1.5	$ 1.1
Weighted-average amortization period of intangible assets	2 years 1 month 6 days

Balance sheet Components - Sche

Balance sheet Components - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Indefinite Lived Intangible Assets By Major Class [Line Items]
Gross intangible assets	$ 22,028	$ 22,028
Accumulated amortization	(10,943)	(9,447)
Intangible assets, net	11,085	12,581
Automation platform software
Indefinite Lived Intangible Assets By Major Class [Line Items]
Gross intangible assets	7,200	7,200
Multimodal software technology
Indefinite Lived Intangible Assets By Major Class [Line Items]
Gross intangible assets	4,900	4,900
System simulation software technology
Indefinite Lived Intangible Assets By Major Class [Line Items]
Gross intangible assets	4,600	4,600
Other intangibles
Indefinite Lived Intangible Assets By Major Class [Line Items]
Gross intangible assets	$ 5,328	$ 5,328

Balance sheet Components - Sc_2

Balance sheet Components - Schedule of Estimated Future Amortization Expense of Acquired Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
2023 (remainder)	$ 4,537
2024	4,382
2025	2,166
Intangible assets, net	$ 11,085	$ 12,581

Balance sheet Components - Sc_3

Balance sheet Components - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Prepaid equipment	$ 4,883	$ 4,525
Prepaid software	5,180	5,522
Prepaid taxes	2,048	1,273
Prepaid insurance	7,675	7,702
Other	2,432	1,138
Total	$ 22,218	$ 20,160

Balance sheet Components - Sc_4

Balance sheet Components - Schedule of Other Noncurrent Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Contractual agreement asset	$ 59,611	$ 59,611
Long term prepaid insurance	2,360	3,770
Other non-current assets	703	819
Total	$ 62,674	$ 64,200

Balance sheet Components - Sc_5

Balance sheet Components - Schedule of Accrued and Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Vendor related accruals	$ 8,462	$ 7,508
Payroll accruals	9,778	5,992
Acquisition-related obligation accrual	2,167	2,167
Other accruals and current liabilities	2,437	3,116
Total	$ 22,844	$ 18,783

Stock Warrants and Earnout Sh_3

Stock Warrants and Earnout Shares - Additional Information (Details) $ / shares in Units, $ in Thousands			3 Months Ended
	Oct. 07, 2022 USD ($) tradingDay $ / shares shares	Aug. 10, 2021 USD ($) $ / shares shares	Mar. 31, 2023 USD ($) $ / shares shares	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($) $ / shares
Class of Warrant or Right [Line Items]
Common stock, par value (in dollars per share)			$ 0.0001		$ 0.0001
Warrants exercised (in shares) | shares			0
Warrant liability | $			$ 37,814		$ 28,783
Gain (Loss) from change in fair value of warrants and earnout shares | $			(22,043)	$ 16,814
Earnout Shares Liability | $			57,094		$ 44,055
Common Stock
Class of Warrant or Right [Line Items]
Shares sold and issued in connection with agreement (in shares) | shares	11,044,232
Shares issued, price per share (in dollars per share)	$ 5.4327
Shares sold and issued in connection with agreement | $	$ 60,000
Common Stock
Class of Warrant or Right [Line Items]
Lock-up and transfer of common shares (in shares) | shares		17,130,000
Public Warrants
Class of Warrant or Right [Line Items]
Warrants issued to sponsor (in shares) | shares		17,250,000
Warrants and rights outstanding, term		5 years
Warrant liability | $		$ 32,800
Gain (Loss) from change in fair value of warrants and earnout shares | $			$ (2,900)	1,600
Public Warrants | Common Stock
Class of Warrant or Right [Line Items]
Common stock, par value (in dollars per share)		$ 0.0001
Class of warrants exercise price per share (in dollars per share)			$ 11.50
Private Placement Warrants
Class of Warrant or Right [Line Items]
Warrants issued to sponsor (in shares) | shares		11,533,333
Warrants and rights outstanding, term		5 years
Warrant liability | $		$ 21,900
Gain (Loss) from change in fair value of warrants and earnout shares | $			$ (1,900)	1,000
Private Placement Warrants | Common Stock
Class of Warrant or Right [Line Items]
Common stock, par value (in dollars per share)		$ 0.0001
Class of warrants exercise price per share (in dollars per share)			$ 11.50
Earnout Shares
Class of Warrant or Right [Line Items]
Warrants and rights outstanding, term		10 years
Gain (Loss) from change in fair value of warrants and earnout shares | $			$ (13,000)	$ 19,400
Percentage of shares held for sale			20%
Earnout shares vested (in shares) | shares			0
Earnout Shares Liability | $		$ 149,900
Earnout Shares | Minimum
Class of Warrant or Right [Line Items]
Number of trading days			20 days
Earnout Shares | Maximum
Class of Warrant or Right [Line Items]
Number of trading days			30 days
Earnout Shares | Tranche One
Class of Warrant or Right [Line Items]
Weighted average price per share (in dollars per share)			$ 12
Earnout Shares | Tranche Two
Class of Warrant or Right [Line Items]
Weighted average price per share (in dollars per share)			18
Earnout Shares | Tranche Three
Class of Warrant or Right [Line Items]
Weighted average price per share (in dollars per share)			24
Earnout Shares | Tranche Four
Class of Warrant or Right [Line Items]
Weighted average price per share (in dollars per share)			32
Earnout Shares | Tranche Five
Class of Warrant or Right [Line Items]
Weighted average price per share (in dollars per share)			$ 50
Delta Warrants
Class of Warrant or Right [Line Items]
Warrant liability | $	$ 16,100
Gain (Loss) from change in fair value of warrants and earnout shares | $			$ (4,200)
Class of warrant or right outstanding (in shares) | shares	12,833,333
Value cap adjustment period	30 days
Stock price trigger percent	150%
Value cap adjustment period, threshold business days | tradingDay	10
Delta Warrants | Tranche One
Class of Warrant or Right [Line Items]
Class of warrant or right outstanding (in shares) | shares	7,000,000
Delta Warrants | Tranche Two
Class of Warrant or Right [Line Items]
Class of warrant or right outstanding (in shares) | shares	5,833,333
Delta Warrants | Common Stock | Tranche One
Class of Warrant or Right [Line Items]
Class of warrants exercise price per share (in dollars per share)	$ 10
Delta Warrants | Common Stock | Tranche Two
Class of Warrant or Right [Line Items]
Class of warrants exercise price per share (in dollars per share)	$ 12

Stock Warrants and Earnout Sh_4

Stock Warrants and Earnout Shares - Schedule of Assumptions Used to Estimate Fair Value of Earnout Shares Liability (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Class of Warrant or Right [Line Items]
Expected volatility	70.60%	73.70%
Risk-free interest rate	3.52%	3.92%
Dividend rate	0%	0%
Expected term (years)	8 years 4 months 9 days	8 years 7 months 9 days
Delta Warrants
Class of Warrant or Right [Line Items]
Expected volatility	78.40%	75.10%
Risk-free interest rate	3.49%	3.89%
Dividend rate	0%	0%
Expected term (years)	9 years 6 months	9 years 9 months 18 days

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands				1 Months Ended	3 Months Ended		12 Months Ended
	Feb. 27, 2023	Jan. 01, 2023	Aug. 10, 2021	Nov. 30, 2016	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Additional stock-based compensation					$ 17,258	$ 19,429
Stock repurchase liability					$ 300		$ 400
2021 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of share outstanding					4%
Additional shares authorized (in shares)					24,904,113
2021 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of share outstanding			0.50%
Incentive Stock Options | Two Thousand And Sixteen Stock Option And Grant Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares vesting period				6 years
Award cliff off period				1 year
Incentive Stock Options | Two Thousand And Sixteen Stock Option And Grant Plan | Grantee Owns Ten Percent of Voting Rights
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of shareholding by grantee				10%
Contractual term				5 years
Percentage of stockholders on exercise price of option granted				10%
Purchase price of common stock expressed as a percentage of its fair value				110%
Performance Shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Target bonus threshold	30%
Increase in target amounts	one-third
Additional stock-based compensation					$ 3,300	7,300
Employee Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Purchase price of common stock expressed as a percentage of its fair value			85%
ESPP stock issued during the period (in shares)					0
Employee Stock | 2021 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Additional shares authorized (in shares)		3,113,014
Additional stock-based compensation					$ 800	$ 0
Options to purchase common stock and unvested restricted stock awards
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares vesting period					6 years
Restricted stock shares weighted average repurchase price per share					$ 0.10		$ 0.10
Options to purchase common stock and unvested restricted stock awards | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares to be repurchased (in shares)					3,338,985		3,923,509
Other Stock Based Awards | Series C Preferred Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Payments for advisory services shares (in shares)					2,677,200
Other Stock Based Awards | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares subject to vesting conditions					1,895,180	2,007,595
Earnout Shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Warrants and rights outstanding, term			10 years

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Nonvested Restricted Stock Units Activity (Details) - Unvested restricted stock units - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Number of Units
Beginning balance (in shares)	28,537,127
Granted (in shares)	1,973,570
Vested (in shares)	(5,839,302)
Forfeited (in shares)	(815,705)
Ending balance (in shares)	23,855,690
Weighted-Average Grant Date Fair Value Per Share
Beginning balance (in dollars per share)	$ 5.75
Granted (in dollars per share)	3.84
Vested (in dollars per share)	4.58
Forfeited (in dollars per share)	6.32
Ending balance (in dollars per share)	$ 5.86
Aggregate Intrinsic Value	$ 103,534	$ 95,599

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based payment arrangement, expense	$ 17,258	$ 19,429
Research and development expenses
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based payment arrangement, expense	13,044	14,722
Selling, general and administrative expenses
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based payment arrangement, expense	$ 4,214	$ 4,707

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
SummerBio
Related Party Transaction [Line Items]
Expenses and related payments		$ 0.6
Office Space And Certain Utilities And Maintenance Services
Related Party Transaction [Line Items]
Expenses and related payments	$ 0.2	$ 0.2

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Numerator:
Net loss attributable to common stockholders	$ (113,393)	$ (62,319)
Denominator:
Weighted average number of shares outstanding, basic (in shares)	605,184,671	579,090,606
Weighted average number of shares outstanding, diluted (in shares)	605,184,671	579,090,606
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (0.19)	$ (0.11)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (0.19)	$ (0.11)

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Common Stockholders - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	73,760,334	93,766,774
Common stock warrants
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	28,783,333	28,783,333
Unvested restricted stock units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	23,855,690	18,964,922
Options to purchase common stock and unvested restricted stock awards
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	17,782,326	22,622,456
Unvested early exercised common stock options
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	3,338,985	6,266,063
Earnout Shares
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)		17,130,000

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ / shares in Units, $ in Millions	May 03, 2023	Mar. 31, 2023	Dec. 31, 2022
Subsequent Event [Line Items]
Common stock, par value (in dollars per share)		$ 0.0001	$ 0.0001
Subsequent Event | Direct Offering
Subsequent Event [Line Items]
Sale of stock, number of shares issued in transaction (in shares)	43,985,681
Common stock, par value (in dollars per share)	$ 0.0001
Sale of stock, price per share (in dollars per share)	$ 4.10
Sale of stock, consideration received on transaction	$ 180.2